These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25107927)

  • 21. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects.
    Abrahamson DR; Isom K; Roach E; Stroganova L; Zelenchuk A; Miner JH; St John PL
    J Am Soc Nephrol; 2007 Sep; 18(9):2465-72. PubMed ID: 17699809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
    Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA
    J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alport syndrome and thin basement membrane nephropathy.
    Thorner PS
    Nephron Clin Pract; 2007; 106(2):c82-8. PubMed ID: 17570934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs.
    Ruggenenti P
    Nephron; 2023; 147(8):465-469. PubMed ID: 36731435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal, auricular, and ocular outcomes of Alport syndrome and their current management.
    Zhang Y; Ding J
    Pediatr Nephrol; 2018 Aug; 33(8):1309-1316. PubMed ID: 28864840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Alport Syndrome: A Primer for Clinicians.
    Martínez-Pulleiro R; García-Murias M; Fidalgo-Díaz M; García-González MÁ
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laminin-1 reexpression in Alport mouse glomerular basement membranes.
    Abrahamson DR; Prettyman AC; Robert B; St John PL
    Kidney Int; 2003 Mar; 63(3):826-34. PubMed ID: 12631063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glomerular filtration and podocyte tensional homeostasis: importance of the minor type IV collagen network.
    Bersie-Larson LM; Gyoneva L; Goodman DJ; Dorfman KD; Segal Y; Barocas VH
    Biomech Model Mechanobiol; 2020 Dec; 19(6):2433-2442. PubMed ID: 32462439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature.
    Gomes AM; Lopes D; Almeida C; Santos S; Malheiro J; Lousa I; Caldas Afonso A; Beirão I
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alport syndrome--insights from basic and clinical research.
    Kruegel J; Rubel D; Gross O
    Nat Rev Nephrol; 2013 Mar; 9(3):170-8. PubMed ID: 23165304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A COL4A3 gene mutation and post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.
    Kalluri R; van den Heuvel LP; Smeets HJ; Schroder CH; Lemmink HH; Boutaud A; Neilson EG; Hudson BG
    Kidney Int; 1995 Apr; 47(4):1199-204. PubMed ID: 7783419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice.
    Heidet L; Borza DB; Jouin M; Sich M; Mattei MG; Sado Y; Hudson BG; Hastie N; Antignac C; Gubler MC
    Am J Pathol; 2003 Oct; 163(4):1633-44. PubMed ID: 14507670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteinuria: detection and role in native renal disease progression.
    Gorriz JL; Martinez-Castelao A
    Transplant Rev (Orlando); 2012 Jan; 26(1):3-13. PubMed ID: 22137726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complexities of the glomerular basement membrane.
    Naylor RW; Morais MRPT; Lennon R
    Nat Rev Nephrol; 2021 Feb; 17(2):112-127. PubMed ID: 32839582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathology, ultrastructure, and clinical phenotypes in thin glomerular basement membrane disease variants.
    Liapis H; Gökden N; Hmiel P; Miner JH
    Hum Pathol; 2002 Aug; 33(8):836-45. PubMed ID: 12203217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alport syndrome: from bedside to genome to bedside.
    Kashtan CE; Michael AF
    Am J Kidney Dis; 1993 Nov; 22(5):627-40. PubMed ID: 8238007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members.
    Savige J
    Pediatr Nephrol; 2020 Jan; 35(1):59-66. PubMed ID: 30506145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel model of autosomal dominant Alport syndrome in Dalmatian dogs.
    Hood JC; Huxtable C; Naito I; Smith C; Sinclair R; Savige J
    Nephrol Dial Transplant; 2002 Dec; 17(12):2094-8. PubMed ID: 12454218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome.
    Akihisa T; Sato M; Wakayama Y; Taneda S; Horita S; Hirose O; Makabe S; Kataoka H; Mori T; Sohara E; Uchida S; Nitta K; Mochizuki T
    Kidney Med; 2019; 1(6):391-396. PubMed ID: 32734219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.
    Dufek B; Meehan DT; Delimont D; Cheung L; Gratton MA; Phillips G; Song W; Liu S; Cosgrove D
    Kidney Int; 2016 Aug; 90(2):300-310. PubMed ID: 27165837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.